Literature DB >> 62019

Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway.

N R Cooper, F C Jensen, R M Welsh, M B Oldstone.   

Abstract

In earlier studies we found that human serum, but not serum from multiple other species, inactivated and lysed oncornaviruses from a number of diverse sources in the apparent absence of antibody. A detailed analysis of the role of the human complement (C) system in mediating this lytic process indicates that human C1q interacts directly, in the absence of immunoglobulin, with oncornaviruses. Binding of C1 via C1q in this manner leads to activation of C1r, C1s, and thus of the classical C pathway. Integrity of the classical pathway is an absolute requirement for lysis although activation of the alternative pathway considerably amplifies the amount of lysis obtained, possibly through involvement of the C3b-dependent feedback mechanism. Activation of C is accompanied by deposition of C components on the viral surface and lysis on completion of the C reaction sequence. Thus in this system, the C1q subunit of C1 subserves a specific recognition function normally associated with antibody. This ability of human serum to inactivate oncornaviruses may represent a natural defense mechanism operative in vivo which deters expression of intact oncornaviruses in human malignancies.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 62019      PMCID: PMC2190433          DOI: 10.1084/jem.144.4.970

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  46 in total

1.  INFECTION OF HUMAN AND SIMIAN TISSUE CULTURES WITH ROUS SARCOMA VIRUS.

Authors:  F C JENSEN; A J GIRARDI; R V GILDEN; H KOPROWSKI
Journal:  Proc Natl Acad Sci U S A       Date:  1964-07       Impact factor: 11.205

2.  Presence of antibody to a primate RNA virus in human plasma.

Authors:  B S Kim
Journal:  Nature       Date:  1975-10-16       Impact factor: 49.962

3.  C-type virus antigens detected by immunofluorescence in human bone tumour cultures.

Authors:  C Zurcher; J Brinkhof; P Bentvelzen; J C De Man
Journal:  Nature       Date:  1975-04-03       Impact factor: 49.962

4.  Viral-related information in oncornavirus-lik particles isolated from cultures of marrow cells from leukemic patients in relapse and remission.

Authors:  T W Mak; S Kurtz; J Manaster; D Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

5.  Isolation of infectious C-type oncornavirus from human leukaemic bone marrow cells.

Authors:  K Nooter; A M Aarssen; P Bentvelzen; F G De Groot; F G Van Pelt
Journal:  Nature       Date:  1975-08-14       Impact factor: 49.962

6.  Human serum lyses RNA tumour viruses.

Authors:  R M Welsh; N R Cooper; F C Jensen; M B Oldstone
Journal:  Nature       Date:  1975-10-16       Impact factor: 49.962

Review 7.  Horizontally and vertically transmitted oncornaviruses of cats.

Authors:  M Essex
Journal:  Adv Cancer Res       Date:  1975       Impact factor: 6.242

8.  Primate type C virus p30 antigen in cells from humans with acute leukemia.

Authors:  C J Sherr; G J Todaro
Journal:  Science       Date:  1975-03-07       Impact factor: 47.728

9.  Physicochemical and functional characterization of the C1r subunit of the first complement component.

Authors:  R J Ziccardi; N R Cooper
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

10.  C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum.

Authors:  A T Sobel; V A Bokisch; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

View more
  68 in total

1.  Retrovirus-induced feline pure red cell aplasia. Hematopoietic progenitors are infected with feline leukemia virus and erythroid burst-forming cells are uniquely sensitive to heterologous complement.

Authors:  J L Abkowitz; R D Holly; C K Grant
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

2.  Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity.

Authors:  Jerome P Jayasekera; E Ashley Moseman; Michael C Carroll
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

3.  Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.

Authors:  Young-Chan Kwon; Hangeun Kim; Keith Meyer; Adrian M Di Bisceglie; Ranjit Ray
Journal:  J Immunol       Date:  2016-06-29       Impact factor: 5.422

Review 4.  Vectors for cancer gene therapy.

Authors:  J Zhang; S J Russell
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

5.  Absence of the eighth component of complement in association with systemic lupus erythematosus-like disease.

Authors:  H E Jasin
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

6.  Antibody-independent activation of the classical pathway of complement by Epstein-Barr virus.

Authors:  H Martin; I McConnell; B Gorick; N C Hughes-Jones
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

7.  Perivascular deposits of serum proteins in cerebral cortex in vascular dementia.

Authors:  I Alafuzoff; R Adolfsson; I Grundke-Iqbal; B Winblad
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

8.  Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies.

Authors:  P Vanguri; C L Koski; B Silverman; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

9.  Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.

Authors:  J Schmitz; J P Zimmer; B Kluxen; S Aries; M Bögel; I Gigli; H Schmitz
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

10.  Nonspecific reactions in the hemagglutination inhibition test for detection of rubella antibodies.

Authors:  D B Budzko; D F Jelinek; B W Wilcke
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.